Covestor
GLUE icon

Covestor’s Monte Rosa Therapeutics GLUE Stock Holding History

Covestor’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$39K Buy
3,303
+35
+1% +$600 0.02% 863
2026
Q2 		$79K Buy
3,268
+3,263
+65,260% +$61.7K 0.05% 503
2026
Q1 		$0 Sell
5
-382
-99% -$7.3K ﹤0.01% 2455
2025
Q4 		$6K Buy
+387
New +$5.22K ﹤0.01% 1813

Other funds holding GLUE

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Alphabet Inc
Alphabet Inc Mountain View, California $88.3B AUM 46.07% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Profund Advisors
Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
AlphaCentric Advisors
AlphaCentric Advisors San Juan, Puerto Rico $113M AUM 27.37% 1-Year Est. Return

Covestor's GLUE Position: Q3 2026 in Review

Covestor increased its Monte Rosa Therapeutics (GLUE) stake by 1.1% in Q3 2026, buying an estimated $600 and bringing the position to 3,303 shares worth $39K. The position accounts for 0.02% of the portfolio, ranked #863.

Covestor first reported a position in GLUE in Q4 2025 and has held it in 4 quarters since. The position peaked at $79K in Q2 2026. 47 funds tracked by Wall St. Rank hold GLUE as of Q3 2026.

  • Covestor held 3,303 shares of Monte Rosa Therapeutics worth $39K as of Q3 2026.
  • Covestor bought 35 Monte Rosa Therapeutics shares in Q3 2026, an estimated $600.
  • Monte Rosa Therapeutics made up 0.02% of Covestor's portfolio in Q3 2026, its #863 holding.
  • Covestor first reported a position in Monte Rosa Therapeutics in Q4 2025 and has held it in 4 quarters since.
  • Covestor's Monte Rosa Therapeutics position peaked at $79K in Q2 2026.
  • 47 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q3 2026.

Based on Covestor's 13F filing for Q3 2026, filed 30 Oct 2026.